doi: 10.1021/jm020969t.
Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin
Affiliations
- PMID: 12593655
- DOI: 10.1021/jm020969t
Item in Clipboard
Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin
J Med Chem.
.
Abstract
A new series of NSAIDs in which aspirin is joined by an ester linkage to furoxan moieties, with different ability to release NO, were synthesized and tested for NO-releasing, antiinflammatory, antiaggregatory, and ulcerogenic properties. Related furazan derivatives, aspirin, its propyl ester, and its gamma-nitrooxypropyl ester were taken as references. All the products described present an antiinflammatory trend, maximized in derivatives 12, 16, and 17, they are devoid of acute gastrotoxicity, principally due to their ester nature, and show an antiplatelet activity primarily determined by their ability to release NO. They do not behave as aspirin prodrugs in human serum.
Similar articles
-
A new class of ibuprofen derivatives with reduced gastrotoxicity.J Med Chem. 2001 Oct 11;44(21):3463-8. doi: 10.1021/jm0108799. J Med Chem. 2001. PMID: 11585451
-
(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins.J Med Chem. 2009 Aug 27;52(16):5058-68. doi: 10.1021/jm900587h. J Med Chem. 2009. PMID: 20560642
-
Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: synthesis, biological evaluation and nitric oxide release studies.Bioorg Med Chem Lett. 2009 Jun 1;19(11):3014-8. doi: 10.1016/j.bmcl.2009.04.059. Epub 2009 Apr 20. Bioorg Med Chem Lett. 2009. PMID: 19419861
-
Physiological mediators in nonsteroidal anti-inflammatory drugs (NSAIDs)-induced impairment of gastric mucosal defense and adaptation. Focus on nitric oxide and lipoxins.J Physiol Pharmacol. 2008 Aug;59 Suppl 2:89-102. J Physiol Pharmacol. 2008. PMID: 18812631 Review.
-
Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders.Cardiovasc Drug Rev. 2006 Summer;24(2):148-68. doi: 10.1111/j.1527-3466.2006.00148.x. Cardiovasc Drug Rev. 2006. PMID: 16961726 Review.
Cited by
-
The evolving landscape for cellular nitric oxide and hydrogen sulfide delivery systems: A new era of customized medications.Biochem Pharmacol. 2020 Jun;176:113931. doi: 10.1016/j.bcp.2020.113931. Epub 2020 Mar 26. Biochem Pharmacol. 2020. PMID: 32224139 Free PMC article. Review.
-
A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages.J Inflamm (Lond). 2008 Jul 31;5:12. doi: 10.1186/1476-9255-5-12. J Inflamm (Lond). 2008. PMID: 18671842 Free PMC article.
-
Pharmacological evaluation and preliminary pharmacokinetics studies of a new diclofenac prodrug without gastric ulceration effect.Int J Mol Sci. 2012 Nov 19;13(11):15305-20. doi: 10.3390/ijms131115305. Int J Mol Sci. 2012. PMID: 23203127 Free PMC article.
-
Pharmacokinetics and pharmacodynamics of nitric oxide mimetic agents.Nitric Oxide. 2019 Mar 1;84:69-78. doi: 10.1016/j.niox.2019.01.001. Epub 2019 Jan 11. Nitric Oxide. 2019. PMID: 30641123 Free PMC article. Review.
-
Furoxans (1,2,5-oxadiazole-N-oxides) as novel NO mimetic neuroprotective and procognitive agents.J Med Chem. 2012 Apr 12;55(7):3076-87. doi: 10.1021/jm201504s. Epub 2012 Mar 30. J Med Chem. 2012. PMID: 22429006 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
